Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Functional characterization of the biogenic amine transporters on human macrophages
Phillip M. Mackie, Adithya Gopinath, Dominic M. Montas, Alyssa Nielsen, Aidan Smith, Rachel A. Nolan, Kaitlyn Runner, Stephanie M. Matt, John McNamee, Joshua E. Riklan, Kengo Adachi, Andria Doty, Adolfo Ramirez-Zamora, Long Yan, Peter J. Gaskill, Wolfgang J. Streit, Michael S. Okun, Habibeh Khoshbouei
Phillip M. Mackie, Adithya Gopinath, Dominic M. Montas, Alyssa Nielsen, Aidan Smith, Rachel A. Nolan, Kaitlyn Runner, Stephanie M. Matt, John McNamee, Joshua E. Riklan, Kengo Adachi, Andria Doty, Adolfo Ramirez-Zamora, Long Yan, Peter J. Gaskill, Wolfgang J. Streit, Michael S. Okun, Habibeh Khoshbouei
View: Text | PDF
Research Article Inflammation Neuroscience

Functional characterization of the biogenic amine transporters on human macrophages

  • Text
  • PDF
Abstract

Monocyte-derived macrophages (MDMs) are key players in tissue homeostasis and diseases regulated by a variety of signaling molecules. Recent literature has highlighted the ability for biogenic amines to regulate macrophage functions, but the mechanisms governing biogenic amine signaling in and around immune cells remain nebulous. In the CNS, biogenic amine transporters are regarded as the master regulators of neurotransmitter signaling. While we and others have shown that macrophages express these transporters, relatively little is known of their function in these cells. To address these knowledge gaps, we investigated the function of norepinephrine transporter (NET) and dopamine transporter (DAT) on human MDMs. We found that both NET and DAT are present and can uptake substrate from the extracellular space at baseline. Not only was DAT expressed in cultured MDMs, but it was also detected in a subset of intestinal macrophages in situ. Surprisingly, we discovered a NET-independent, DAT-mediated immunomodulatory mechanism in response to LPS. LPS induced reverse transport of dopamine through DAT, engaging an autocrine/paracrine signaling loop that regulated the macrophage response. Removing this signaling loop enhanced the proinflammatory response to LPS. Our data introduce a potential role for DAT in the regulation of innate immunity.

Authors

Phillip M. Mackie, Adithya Gopinath, Dominic M. Montas, Alyssa Nielsen, Aidan Smith, Rachel A. Nolan, Kaitlyn Runner, Stephanie M. Matt, John McNamee, Joshua E. Riklan, Kengo Adachi, Andria Doty, Adolfo Ramirez-Zamora, Long Yan, Peter J. Gaskill, Wolfgang J. Streit, Michael S. Okun, Habibeh Khoshbouei

×

Figure 8

LPS-regulation of DAT activity is CD14 dependent but TLR4 independent.

Options: View larger image (or click on image) Download as PowerPoint
LPS-regulation of DAT activity is CD14 dependent but TLR4 independent.
(...
(A) Representative 40× images of macrophages that were unstimulated, LPS-stimulated, or cotreated with LPS and CLI095 (TLR4 antagonist), LPS and a neutralizing monoclonal antibody against CD14 (AbCD14), or LPS and Iaxo102 (a CD14 antagonist) and assayed for DAT-mediated IDT307. (B) DAT-dependent IDT307 uptake was calculated via blocker subtraction showing decreased DAT-dependent uptake in LPS-stimulated macrophages. Cotreatment with LPS and either AbCD14 or Iaxo102 prevented the LPS-induced reduction of DAT-dependent IDT307 uptake. (C and D) Quantification of rate (C, average slope) and magnitude (D, AUC) of DAT-dependent IDT307 uptake shown in B showed a significant decrease in the DAT-mediated IDT307 uptake following LPS stimulation (average slope, P = 0.005; AUC, P = 0.01). CLI095 did not prevent the LPS reduction of DAT-dependent uptake (AUC, P > 0.9), whereas cotreatment with either mAbCD14 or CD14 antagonist Iaxo102 rescued the DAT-dependent uptake back to unstimulated levels (average slope, P = 0.05; AUC, P = 0.06). Data are from n = 6–19 experiments/group, and statistical analysis was performed using Kruskal-Wallis tests with Dunn’s test for multiple comparisons. (E) Representative 60× images of cultured human macrophages that were either unstimulated, LPS-stimulated, or treated with LPS and mAbCD14 and labeled for CTxB-555 and DAT. (F) Quantifying colocalization between CTxB55 and DAT using Pearson’s correlation coefficient shows that AbCD14 reversed the increased DAT–CTxB-555 colocalization back to unstimulated levels (P = 0.03, Mann Whitney U test). Data in E and F are from n = 4–8 experiments/group. (G) The DAT-dependent dopamine efflux measured via simultaneous whole-cell patch-clamp and amperometry as in Figure 7 shows no significant increase in basal dopamine efflux between unstimulated macrophages and macrophages treated with LPS + mAbCD14 (P = 0.7, Welch’s 2-tailed t test, n = 5 experiments/group).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts